Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in children and adolescents in Africa: A randomised, placebo-controlled, multicentre Phase II clinical trial

BACKGROUND: Reoccurring Ebola outbreaks in West and Central Africa have led to serious illness and death in thousands of adults and children. The objective of this study was to assess safety, tolerability, and immunogenicity of the heterologous 2-dose Ad26.ZEBOV, MVA-BN-Filo vaccination regimen in a...

Descripción completa

Detalles Bibliográficos
Autores principales: Anywaine, Zacchaeus, Barry, Houreratou, Anzala, Omu, Mutua, Gaudensia, Sirima, Sodiomon B., Eholie, Serge, Kibuuka, Hannah, Bétard, Christine, Richert, Laura, Lacabaratz, Christine, McElrath, M. Juliana, De Rosa, Stephen C., Cohen, Kristen W., Shukarev, Georgi, Katwere, Michael, Robinson, Cynthia, Gaddah, Auguste, Heerwegh, Dirk, Bockstal, Viki, Luhn, Kerstin, Leyssen, Maarten, Thiébaut, Rodolphe, Douoguih, Macaya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8752100/
https://www.ncbi.nlm.nih.gov/pubmed/35015777
http://dx.doi.org/10.1371/journal.pmed.1003865

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8752100/
https://www.ncbi.nlm.nih.gov/pubmed/35015777
http://dx.doi.org/10.1371/journal.pmed.1003865

Ejemplares similares